Ads
related to: breathing problems with multiple myeloma prognosis 5 years- Treatment Schedule
Learn How This Treatment Is Given
See the Infusion Schedule
- Phase 3 Trials
See Study Results
From the Latest Trial
- Patient Support Program
Eligible Patients May Qualify
for Financial Assistance
- Safety Information
Read Safety Information
for Patients and Caregivers
- Treatment Schedule
Search results
Results From The WOW.Com Content Network
MGUS is a relatively stable condition afflicting 3% of people aged 50 and 5% of people aged 70; it progresses to multiple myeloma at a rate of 0.5–1% cases per year; smoldering multiple myeloma does so at a rate of 10% per year for the first 5 years, but then falls off sharply to 3% per year for the next 5 years and thereafter to 1% per year.
Crow–Fukase syndrome, Osteosclerotic myeloma, PEP syndrome, Polyneuropathy-endocrinopathy-plasma cell dyscrasia syndrome, Takatsuki syndrome. [1] Multiple myeloma is usually diagnosed because malignant plasma cells continue to produce an antibody that can be detected as a paraprotein. Specialty: Oncology Symptoms
Smouldering myeloma is a disease classified as intermediate in a spectrum of step-wise progressive diseases termed plasma cell dyscrasias.In this spectrum of diseases, a clone of plasma cells secreting monoclonal paraprotein (also termed myeloma protein or M protein) causes the relatively benign disease of monoclonal gammopathy of undetermined significance.
Gradual cranial migration of the neurological deficits (problems relating to the nervous system), is known as ascending syndrome and is said to be a typical feature of diffuse myelomalacia. Although clinical signs of myelomalacia are observed within the onset (start) of paraplegia, sometimes they may become evident only in the post-operative ...
Around 35,000 multiple myeloma cases are reported each year in the U.S. Older adults, men and people with obesity have a higher risk of the disease, though doctors are still trying to understand ...
The typical age of onset is 70 years. [4] The prognosis depends on the type of cells affected, the number of blasts in the bone marrow or blood, and the changes present in the chromosomes of the affected cells. [3] The average survival time following diagnosis is 2.5 years. [4]